

A novel alpha-1 antitrypsin gene variant in a patient with Kartagener's syndrome: a case report

Levent Ozdemir, Burcu Ozdemir, Savaş Gegin

Department of Pulmonology,
Samsun Training and Research
Hospital, Samsun, Turkey

Alpha-1 antitrypsin deficiency (AATD) is a rare autosomal co-dominant disease caused by mutations in the *SERPINA1* gene. The alleles most frequently associated with AATD are protease inhibitors S and Z. Here, we report on a 35-year-old woman diagnosed with Kartagener's syndrome and subsequently referred for bronchiectasis testing. She was identified with a hitherto unreported AATD mutation: a heterozygous variant rs1460874866 in a previously undefined exon 4 (NM_001127701.1) of the *SERPINA1* gene. Although Kartagener's syndrome is a genetic cause of bronchiectasis, patients with this syndrome are recommended to undergo AATD testing.

Received: November 2, 2023

Accepted: October 16, 2024

Correspondence to:

Savaş Gegin
Samsun Training and Research
Hospital
55090 İlkadım/Samsun, Turkey
gegin@hotmail.com

Kartagener's syndrome is a genetic condition characterized by the triad of bronchiectasis, *situs inversus*, and sinusitis. It is inherited as an autosomal recessive trait (1). Bronchiectasis is one of the pulmonary symptoms associated with a deficiency in alpha-1 antitrypsin (AAT), a primary protease inhibitor that protects the lung parenchyma from proteolytic assaults (2). AAT deficiency (AATD) is a prevalent but poorly understood autosomal co-dominant disease characterized by low serum AAT levels caused by mutations in the *SERPINA1* gene. Despite the identification of over 150 *SERPINA1* variants to date, novel genetic variants have been frequently discovered. In the past decade, researchers have identified 22 new genetic variants associated with *SERPINA1* (3). The 14 allele variants most frequently associated with AAT deficiency are listed in Table 1.

Here, we report on a patient with Kartagener's syndrome who was diagnosed with AAT genotype deficiency and had a previously unidentified heterozygous variant rs1460874866 in the exon 4 (NM_001127701.1) of the *SERPINA1* gene.

CASE REPORT

A 35-year-old woman was examined at our Chest Diseases Polyclinic in February 2023 due to coughing, wheezing, sputum production, and shortness of breath. She had been diagnosed with Kartagener's syndrome in her childhood and had undergone two operations for bronchiectasis. She had no history of smoking, and her fam-

ily history was unremarkable. The respiratory system examination revealed prominent bilateral rales in the right lower zone, with rhonchi present in all zones. Her cardiac apex pulse was observed on the right. The chest x-ray showed the fundal air shadow of the heart and stomach on the right side. Bronchiectatic areas were identified in the right middle-lower and left lower zone. Paranasal sinus tomography revealed sinusitis. On thorax tomography, cystic bronchiectasis was visible in the left lower lobe and the right lung, along with dextrocardia and volume loss. Upper abdominal tomography showed the liver to be located on the left, while the spleen and stomach were on the right (Figure 1A-E). The laboratory parameters were within the reference range. The results of the pulmonary function test were as follows: forced vital capacity 0.84 (26%) and forced expiratory volume in one second 0.81 (30%). Alpha-1 antitrypsin level was 1.1 g/L (reference range: 0.9-2 g/L).

As it is recommended that all patients with Kartagener's syndrome are tested for AATD, the patient was referred for *SERPINA1* genotyping. Fingerprick blood was collected. The genomic DNA from desiccated drop blood samples was replicated by polymerase chain reaction and hybridized with allele-specific probes by using the Luminex xMAP technology (Luminex, Austin, TX, USA). The screening identified a heterozygous variant rs1460874866 in a previously undefined exon 4 (NM_001127701.1) (Figure 2). The patient continues to be followed up regularly at our clinic. The timeline of events and diagnostic procedures is illustrated in Figure 3.

TABLE 1. Frequently detected allelic variants associated in *SERPINA1*.

Frequently detected allelic variants	Nucleotide change	Amino acid change HGVS nomenclature	Amino acid change (alternative name) in the mature protein or affected exons in large indels	SNP code
PI*I	c.187C>T	p.(Arg63Cys)	Arg39Cys	rs28931570
PI*M procida	c.194T>C	p.(Leu65Pro)	Leu41Pro	rs28931569
PI*M malton	c.227_229delTCT	p.(Phe76del)	Phe52del	rs775982338
PI*S iiyama	c.230C>T	p.(Ser77Phe)	Ser53Phe	rs55819880
PI*Q0 granite falls	c.552delC	p.(Tyr184*)	Tyr160*	rs267606950
PI*Q0 west	c.646 + 1G>T	NA	NA	rs751235320
PI*Q0 bellingham	c.721A>T	p.(Lys241*)	Lys217*	rs199422211
PI*F	c.739C>T	p.(Arg247Cys)	Arg223Cys	rs28929470
PI*lowell	c.839A>T	p.(Asp280Val)	Asp256Val	rs121912714
PI*S	c.863A>T	p.(Glu288Val)	Glu264Val	rs17580
PI*Z	c.1096G>A	p.(Glu366Lys)	Glu342Lys	rs28929474
PI*Q0 mattawa	c.1130dupT	p.(Leu377Phefs*24)	Leu353Phefs*24	rs763023697
PI*Q0 clayton	c.1158dupC	p.(Glu387Argfs*14)	Glu363Argfs*14	rs764325655
PI*M heerlen	c.1178C>T	p.(Pro393Leu)	Pro369Leu	rs199422209

*Abbreviations: HGVS – Human Genome Variation Society; SNP – single-nucleotide polymorphism.

DISCUSSION

Bronchiectasis is a chronic respiratory disease characterized by irreversible pathological dilation of the bronchia. Symptoms include recurrent respiratory tract infections, sputum, and cough. The components of the bronchiectasis etiology include primary ciliary dyskinesia (Kartagener’s syndrome) (4), congenital AATD, and cystic fibrosis (5). Bronchiectasis is one of the pulmonary symptoms associated with AATD (6). The prevalence of AATD is 20/100 000 (7). Regardless of smoking status, the World Health Organization recommends that all patients with chronic obstructive pulmonary disease and emphysema undergo testing for AATD. Additionally, individuals who have siblings with liver disease, bronchiectasis, partially reversible asthma, necrotizing panniculitis, and the proteinase inhibitor ZZ (PiZZ) allele are advised to undergo the test (8).

Limited research has been conducted to assess the prevalence of AATD in patients with bronchiectasis. The PiZZ phenotype was detected in 0.5% of 1600 patients, the proteinase inhibitor SZ phenotype in 0.4%, and the proteinase inhibitor MZ phenotype in 3%. Severe AATD was identified in less than 1% of patients with bronchiectasis (9).

Although the identification of rare variants is on the rise, particularly in patients with low AAT concentrations, the clinical significance of these variants remains unknown (3).

Status	Heterozygous
Genome position (GRCh38)	g.94382987
Nucleotide change	c.251C>T
Aminoacid change	p.Ala84Val
Aminoacid change (alternative name) in the mature protein	Ala60Val
Mutation type	Aminoacid change
Associated allele	ND
Predicted protein activity	Unknown
Pathogenicity	Unknown
SNP code	rs1460874866
ClinVar code	Not Reported in ClinVar
Reference	ND
Associated allele (other names)	ND
exon (NM_001127701.1)	exon4

FIGURE 2. The sequencing results obtained for the novel gene variant observed in our patient with Kartagener’s syndrome.




FIGURE 1. (A) Chest x-ray: heart and fundus air shadow on the right; (B) paranasal sinus tomography indicating sinusitis; (C-D) thorax tomography indicating cystic bronchiectasis in both lungs; (E) upper abdomen tomography: the spleen and stomach on the right, the liver on the left.




FIGURE 3. The timeline of diagnostic tests and events. AAT – alpha-1 antitrypsin.

In our case, the treatment indication was not provided for the AAT level, as it was within the reference range. Our investigation obtained no evidence regarding the impact of the detected genetic variant on the patient's health.

In conclusion, we reported on a patient with Kartagener's syndrome identified with an AATD variant that has not been previously identified in our literature review or the reference laboratory archive. Although Kartagener's syndrome is a genetic cause of bronchiectasis, it is recommended that these patients undergo AATD testing.

Funding None.

Ethical considerations The patient provided informed consent for the publication of data and images.

Declaration of authorship All authors conceived and designed the study; acquired the data; analyzed and interpreted the data; drafted the manuscript; critically reviewed the manuscript for important intellectual content; gave approval of the version to be submitted; agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

- Lin CY, Wu FZ. Kartagener syndrome. QJM. 2012;105:375-6. [Medline:21372103 doi:10.1093/qjmed/hcr019](#)
- Oriano M, Amati F, Gramegna A, De Soya A, Mantero M, Sibila O, et al. Protease-antiprotease imbalance in bronchiectasis. Int J Mol Sci. 2021;22:5996. [Medline:34206113 doi:10.3390/ijms22115996](#)
- Renoux C, Odou MF, Tosato G, Teoli J, Abbou N, Lombard C, et al. Description of 22 new alpha-1 antitrypsin genetic variants. Orphanet J Rare Dis. 2018;13:161. [Medline:30223862 doi:10.1186/s13023-018-0897-0](#)
- Lobo LJ, Zariwala MA, Noone PG. Primary ciliary dyskinesia. QJM. 2014;107:691-9. [Medline:24652656 doi:10.1093/qjmed/hcu063](#)
- Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215-21. [Medline:17872489 doi:10.1164/rccm.200703-489OC](#)
- Amati F, Gramegna A, Contarini M, Stainer A, Curcio C, Aliberti S, et al. Genetic and serum screening for alpha-1-antitrypsin deficiency in adult patients with cystic fibrosis: a single-center experience. Biomedicine. 2022;10:3248. [Medline:36552004 doi:10.3390/biomedicine10123248](#)
- Orphanet Report Series – Prevalence of rare diseases: Bibliographic data – January 2022 Number 2. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf. Accessed: October 18, 2024.
- Sevim T, Akyl FT, Aksoy E, Kuver E, Aktaş O. Should alpha-1 antitrypsin deficiency be considered in the etiology of bronchiectasis? Respirol Case Rep. 2016;5:100-3. [doi:10.5505/respirocase.2016.30306](#)
- Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, et al. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax. 2020;75:592-3. [Medline:32303623 doi:10.1136/thoraxjnl-2019-214195](#)